NRx Pharmaceuticals

NRx Pharmaceuticals Announces New Finding from ZYESAMIâ„¢ (aviptadil) Phase 2b/3 Clinical Trial

RADNOR, PA — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) recently announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMIâ„¢ (aviptadil) for the treatment of patients with acute Respiratory Failure due …

NRx Pharmaceuticals Announces New Finding from ZYESAMIâ„¢ (aviptadil) Phase 2b/3 Clinical Trial Read More